146 related articles for article (PubMed ID: 37023372)
1. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
[TBL] [Abstract][Full Text] [Related]
2. KDM1A microenvironment, its oncogenic potential, and therapeutic significance.
Ismail T; Lee HK; Kim C; Kwon T; Park TJ; Lee HS
Epigenetics Chromatin; 2018 Jun; 11(1):33. PubMed ID: 29921310
[TBL] [Abstract][Full Text] [Related]
3. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
4. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Pajtler KW; Weingarten C; Thor T; Künkele A; Heukamp LC; Büttner R; Suzuki T; Miyata N; Grotzer M; Rieb A; Sprüssel A; Eggert A; Schramm A; Schulte JH
Acta Neuropathol Commun; 2013 May; 1():19. PubMed ID: 24252778
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
6. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Stachelscheid J; Jiang Q; Aszyk C; Warner K; Bley N; Müller T; Vydzhak O; Symeonidis K; Crispatzu G; Mayer P; Blakemore SJ; Goehring G; Newrzela S; Hippler S; Robrecht S; Kreuzer KA; Pallasch C; Krüger M; Lechner A; Fischer K; Stilgenbauer S; Beutner D; Hallek M; Auguin D; Hüttelmaier S; Bloehdorn J; Vasyutina E; Herling M
Blood; 2023 Mar; 141(12):1425-1441. PubMed ID: 36179280
[TBL] [Abstract][Full Text] [Related]
7. The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.
Brenner C; Luciani J; Bizet M; Ndlovu M; Josseaux E; Dedeurwaerder S; Calonne E; Putmans P; Cartron PF; Defrance M; Fuks F; Deplus R
Oncotarget; 2016 Sep; 7(37):58939-58952. PubMed ID: 27449289
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.
McGrath JP; Williamson KE; Balasubramanian S; Odate S; Arora S; Hatton C; Edwards TM; O'Brien T; Magnuson S; Stokoe D; Daniels DL; Bryant BM; Trojer P
Cancer Res; 2016 Apr; 76(7):1975-88. PubMed ID: 26837761
[TBL] [Abstract][Full Text] [Related]
9. Germline Lysine-Specific Demethylase 1 (
Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
[TBL] [Abstract][Full Text] [Related]
10. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Harris WJ; Huang X; Lynch JT; Spencer GJ; Hitchin JR; Li Y; Ciceri F; Blaser JG; Greystoke BF; Jordan AM; Miller CJ; Ogilvie DJ; Somervaille TC
Cancer Cell; 2012 Apr; 21(4):473-87. PubMed ID: 22464800
[TBL] [Abstract][Full Text] [Related]
11. Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma.
Lv S; Zhao X; Zhang E; Yan Y; Ma X; Li N; Zou Q; Sun L; Song T
J Biol Chem; 2022 Sep; 298(9):102374. PubMed ID: 35970393
[TBL] [Abstract][Full Text] [Related]
12. Sperm histone H3 lysine 4 trimethylation is altered in a genetic mouse model of transgenerational epigenetic inheritance.
Lismer A; Siklenka K; Lafleur C; Dumeaux V; Kimmins S
Nucleic Acids Res; 2020 Nov; 48(20):11380-11393. PubMed ID: 33068438
[TBL] [Abstract][Full Text] [Related]
13. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW; Piñón JD; Brachtl G; Haginger L; Wang W; Jöhrer K; Tinhofer I; Hartmann TN; Greil R
Cancer Res; 2010 Sep; 70(18):7336-44. PubMed ID: 20823161
[TBL] [Abstract][Full Text] [Related]
14. [Function of histone demethylasehistone lysine-specific demethylase 1A in tumor initiation and progression].
Zhang X; An X; Zhu S; Liu Y
Sheng Wu Gong Cheng Xue Bao; 2020 Feb; 36(2):226-240. PubMed ID: 32147995
[TBL] [Abstract][Full Text] [Related]
15. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
[TBL] [Abstract][Full Text] [Related]
16. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
17. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
[TBL] [Abstract][Full Text] [Related]
18. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Hou X; Li Q; Yang L; Yang Z; He J; Li Q; Li D
Exp Biol Med (Maywood); 2021 Sep; 246(17):1869-1883. PubMed ID: 34171978
[TBL] [Abstract][Full Text] [Related]
19. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia.
Popal W; Boucas J; Peer-Zada AA; Herling M
Leuk Lymphoma; 2010 Aug; 51(8):1375-8. PubMed ID: 20687795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
